


We're Sunk: Antibiotic Use Cannot be Controlled



John Conly MD

**Professor of Medicine, Microbiology & Infectious Diseases
and Pathology & Laboratory Medicine
Centre for Antimicrobial Resistance**

University of Calgary/Calgary Health Region/Calgary Lab Services

Resolution

- Be it resolved that antibiotic use cannot be controlled
- Furthermore antibiotic use need not be controlled
- *“Don’t worry be happy”*

Debate Strategy

- Make scurrilous remarks about the opponent
- Engage in direct personal attacks
- Cite data out of context
- Use half truths
- Use no truth whatsoever
- Use golf ball analogies if any sponsorship scandal arises

Source: Chretien JC

Rules for Debate , House of Commons, Ottawa
Revised 1993, Re-revised G Evans Mar 18 2006

Controlling Antibiotic Use

- Really no need
- Valuable agents for humans, animals, and plants
- Reduce morbidity, mortality humans and animals
- Excellent growth promoters and help boost economy in other sectors

Why Worry about Antibiotic Use

- Natural agents and part of normal ecosystem
- Many new agents under development
- Increasing pharmaceutical funding
- Many alternatives to antibiotics exist

Why Worry about Antibiotic Use

- Resistance issue completely overblown
- Do not be swayed by resistance zealots and sensationalistic media hype

Liberalize Use of Antibiotics


- Decrease in morbidity and mortality
- Greater the number of antibiotics less likelihood treatment failure due to wrong choice
- No studies to date have demonstrated that resistant organisms are associated with increased mortality
- Age and underlying illness are key factors

DR Feikin et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997 Am J Pub Health 2000


Mortality in Community-Acquired Pneumonia Combination Therapy vs Beta-Lactam Alone

Treatment group	Mortality No. (%)	<i>p</i> value	Mortality by PORT group ^a (%)				<i>p</i> value
			I-II	III	IV	V	
All patients (<i>n</i> =1188)							
β-lactam (<i>n</i> =270)	36 (13.3)		0	5.9	13.3*	27*	
β-lactam plus macrolide (<i>n</i> =918)	63 (6.9)	0.001	0	3	5.2*	17.6*	<0.05*
CAP group, no etiological diagnosis (<i>n</i> =759)							
β-lactam (<i>n</i> =180)	28 (15.6)		0	6.3	19.6*	28*	
β-lactam plus macrolide (<i>n</i> =579)	49 (8.5)	0.006	0	1.9	5.9*	22.5*	<0.05*
Pneumococcal pneumonia group (<i>n</i> =255)							
β-lactam (<i>n</i> =61)	6 (9.8)		0	7.7	4.5*	26.7*	
β-lactam plus macrolide (<i>n</i> =194)	11 (5.7)	0.251	0	5.1	6.2*	9.6*	<0.05*
Atypical pneumonia group (<i>n</i> =104)							
β-lactam (<i>n</i> =10)	0 (0)		0	0	0*	0*	
β-lactam plus macrolide (<i>n</i> =94)	3 (3.2)	0.566	0	5.6	2.9*	9.1*	<0.05*

ANTIBIOTIC ECOSYSTEMS



The Benefits of Antibiotics in Meat



[Home](#) > [Preschooler](#) > [Food & Nutrition](#)

Antibiotics in meat: What you need to know



[Printable version](#)




[Send to a friend](#)

By the ParentCenter editorial staff

New Antibacterial Agents Approved Since 1998 in the US

<u>ANTIBACTERIAL</u>	<u>YEAR</u>	<u>NOVEL</u>
Linezolid	2001	Yes
Ertapenem	2001	No
Cefditoren pivoxil	2001	No
Gemifloxacin	2003	No
Daptomycin	2003	Yes
Telithromycin	2004	? Yes

Figure 1: 10-Year Trends in Biomedical Research Spending



The figure shows 10-year trends in biomedical research spending as reflected by the NIH budget (Budget of the United States Government, appendix, FY 1993-2003) and by pharmaceutical companies' research and development (R&D) investment (PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2002/2003).

Source:

FDA

Alternatives to Antibiotics

- Many alternatives exist
- Further lessens concerns over resistance
- Many new alternatives under development
- Probiotics, prebiotics, phage therapy, immunotherapy



Natural Alternatives for Treating Drug-Resistant Bacteria

The Center for Unhindered Living

Alternatives to Antibiotics

How Ancient People Treated Infection

Electrically-Generated Colloidal Silver: Today's Best Natural Antibiotic

More articles to come
on this topic, so check back
frequently!

